company background image
1AI logo

Algorae Pharmaceuticals ASX:1AI Stock Report

Last Price

AU$0.009

Market Cap

AU$15.2m

7D

0%

1Y

-43.8%

Updated

23 Jul, 2024

Data

Company Financials

Algorae Pharmaceuticals Limited

ASX:1AI Stock Report

Market Cap: AU$15.2m

1AI Stock Overview

A biotechnology company, focuses on developing solutions for Parkinson’s disease in Australia.

1AI fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Algorae Pharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Algorae Pharmaceuticals
Historical stock prices
Current Share PriceAU$0.009
52 Week HighAU$0.017
52 Week LowAU$0.008
Beta0.76
11 Month Change-10.00%
3 Month Change-10.00%
1 Year Change-43.75%
33 Year Change-35.71%
5 Year Change-65.38%
Change since IPO-96.40%

Recent News & Updates

Recent updates

How Does Living Cell Technologies' (ASX:LCT) CEO Pay Compare With Company Performance?

Jan 07
How Does Living Cell Technologies' (ASX:LCT) CEO Pay Compare With Company Performance?

Shareholder Returns

1AIAU BiotechsAU Market
7D0%-0.01%-1.2%
1Y-43.8%16.7%8.6%

Return vs Industry: 1AI underperformed the Australian Biotechs industry which returned 16.7% over the past year.

Return vs Market: 1AI underperformed the Australian Market which returned 8.6% over the past year.

Price Volatility

Is 1AI's price volatile compared to industry and market?
1AI volatility
1AI Average Weekly Movement13.8%
Biotechs Industry Average Movement11.3%
Market Average Movement8.2%
10% most volatile stocks in AU Market16.3%
10% least volatile stocks in AU Market3.2%

Stable Share Price: 1AI's share price has been volatile over the past 3 months.

Volatility Over Time: 1AI's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
1987n/aDavid Hainsworthwww.algoraepharma.com

Algorae Pharmaceuticals Limited, a biotechnology company, focuses on developing solutions for Parkinson’s disease in Australia. It is developing NTCELL, an alginate coated capsule to target the treatment of Parkinson’s disease; and AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient treatment for dementia, including Alzheimer’s disease. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023.

Algorae Pharmaceuticals Limited Fundamentals Summary

How do Algorae Pharmaceuticals's earnings and revenue compare to its market cap?
1AI fundamental statistics
Market capAU$15.19m
Earnings (TTM)-AU$2.25m
Revenue (TTM)AU$42.02k

361.4x

P/S Ratio

-6.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1AI income statement (TTM)
RevenueAU$42.02k
Cost of RevenueAU$0
Gross ProfitAU$42.02k
Other ExpensesAU$2.29m
Earnings-AU$2.25m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.0013
Gross Margin100.00%
Net Profit Margin-5,360.41%
Debt/Equity Ratio0%

How did 1AI perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.